No matter how incredible they look and perform, no matter the powertrains fitted under their hoods, or the creature comforts lurking inside, customized half-tons will never be capable of driving their ...
The total treatment was up to 48 weeks and the therapy was based on the administration of M923, Humira or Humira interchanged with M923. For the development of M923, Momenta Pharmaceuticals closely ...
BANNOCKBURN, Ill. and CAMBRIDGE, Mass., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Baxalta Incorporated (NYSE:BXLT) and Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), today announced the initiation of a pivotal ...
Baxalta Inc. BXLT and Momenta Pharmaceuticals, Inc. MNTA announced that their biosimilar candidate M923 has met the primary endpoint in a pharmacokinetic study. Baxalta initiated the trial in Feb 2015 ...
Baxalta Incorporated, a biotechnology company, and Momenta Pharmaceuticals, Inc., a biotechnology company, announced the initiation of a pivotal clinical trial in patients with chronic plaque ...
BANNOCKBURN, Ill. and CAMBRIDGE, Mass., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Baxalta Incorporated (NYSE:BXLT) and Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), today announced that M923 met the primary ...
psoriasis Momenta has announced their adalimumab biosimilar candidate, M923, has met its Phase 3 primary endpoint of at least 75% reduction in the Psoriasis Area and Severity Index (PASI-75) following ...
Please provide your email address to receive an email when new articles are posted on . Baxalta and Momenta Pharmaceuticals announced the beginning of a clinical trial of M923, a proposed biosimilar ...
Sept 27 (Reuters) - Momenta Pharmaceuticals Inc. : * Momenta Pharmaceuticals to regain global development and commercialization rights to M923, a proposed biosimilar of HUMIRA (adalimumab), through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results